Human Immunodeficiency Virus I Infection — Patent Landscape
1
Approved drugs
17
Active US patents
61/100
Avg vulnerability
$2.1B
Annual revenue covered
Originators in Human Immunodeficiency Virus I Infection
Cliff calendar — next 15 years
2
27
11
31
2
32
2
38
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Vocabria
CABOTEGRAVIR
|
GSK | 17 | 61 | $2.1B | 2027-06-30 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11389447 | Vocabria | method of use | 83 | 2027-06-30 |
| 11389447 | Vocabria | method of use | 83 | 2027-06-30 |
| 12138264 | Vocabria | method of use | 81 | 2031-09-15 |
| 12138264 | Vocabria | method of use | 81 | 2031-09-15 |
| RE50189 | Vocabria | method of use | 81 | 2031-11-27 |
| RE50189 | Vocabria | method of use | 81 | 2031-11-27 |
| 11224597 | Vocabria | method of use | 76 | 2031-09-15 |
| 11224597 | Vocabria | method of use | 76 | 2031-09-15 |
| 12178815 | Vocabria | method of use | 75 | 2038-07-18 |
| 12178815 | Vocabria | method of use | 75 | 2038-07-18 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8410103 | Vocabria | composition of matter | 18 | 2031-02-04 |
| 11224597 | Vocabria | formulation | 56 | 2031-09-15 |
| 11389448 | Vocabria | formulation | 61 | 2032-04-13 |
| 11389448 | Vocabria | formulation | 61 | 2032-04-13 |
| 12138264 | Vocabria | formulation | 61 | 2031-09-15 |
| 8410103 | Vocabria | method of use | 68 | 2031-02-04 |
| 8410103 | Vocabria | method of use | 68 | 2031-02-04 |
| 12178815 | Vocabria | method of use | 75 | 2038-07-18 |
| 12178815 | Vocabria | method of use | 75 | 2038-07-18 |
| 11224597 | Vocabria | method of use | 76 | 2031-09-15 |
Related
- Human Immunodeficiency Virus I Infection — full disease profile
- AI Patent Landscape Report — type "human immunodeficiency virus i infection" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner